The New Drug Application (NDA) for the combination of fruquintinib and sintilimab for locally advanced or metastatic renal ...

Background Current treatments with tyrosine kinase inhibitors and immune checkpoint inhibitors have limited efficacy for ...

China NMPA accepts Hutchmed & Innovent’s NDA for fruquintinib in combo with sintilimab to treat advanced renal cell carcinoma: Hong Kong, Shanghai Friday, June 6, 2025, 09:00 Hr ...

Pharmaceutical Co. Ltd.’s LYN/BTK dual inhibitor, DZD-8586, saw tumor shrinkage in 94.1% of patients with relapsed or ...

AstraZeneca (AZ) has announced that its fixed-duration Calquence (acalabrutinib)-based regimens have been approved by the ...

Despite failing to achieve MRD-negativity after induction, patients with Ph+ acute lymphoblastic leukemia treated with ...

The use of tyrosine kinase inhibitors (TKIs) in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) has not produced the same durable clinical benefits ...

US FDA grants orphan drug designation to Sanofi’s rilzabrutinib to treat sickle cell disease: Paris Thursday, June 5, 2025, 11:00 Hrs [IST] The US Food and Drug Administration ( ...

Paris: Sanofi has received orphan drug designation from the US Food and Drug Administration (FDA) for rilzabrutinib, a novel, ...

No writing assistance was utilized in the production of this manuscript. Tyrosine kinase inhibitors (TKIs) are used for the targeted treatment of cancer. TKIs produce a range of serious adverse ...

A fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) in combination with venetoclax, with or without ...

Panelists discuss the primary access challenges in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) treatment, including financial barriers and health care system limitations, and how ...